Symptomatic and Nonamyloid/Tau Based Pharmacologic Treatment for Alzheimer Disease

被引：50

作者：

Aisen, Paul S. ^{[1
]}

Cummings, Jeffrey ^{[2
]}

Schneider, Lon S. ^{[3
]}

机构：

[1] Univ Calif San Diego, San Diego, CA 92093 USA

[2] Cleveland Clin, Cleveland, OH 44195 USA

[3] Univ So Calif, Los Angeles, CA 90007 USA

来源：

COLD SPRING HARBOR PERSPECTIVES IN MEDICINE | 2012年 / 2卷 / 03期

关键词：

MILD COGNITIVE IMPAIRMENT; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; CHOLINESTERASE-INHIBITORS; MEMANTINE TREATMENT; GINKGO-BILOBA; VASCULAR DEMENTIA; CLINICAL-TRIALS; VITAMIN-E; PHASE-II;

D O I：

10.1101/cshperspect.a006395

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

In this work we consider marketed drugs for Alzheimer disease (AD) including acetylcholinesterase inhibitors (AChE-Is) and antiglutamatergic treatment involving the N-methyl-D-aspartate (NMDA) receptor. We discuss medications and substances available for use as cognitive enhancers that are not approved for AD or cognitive impairment, and other neurotransmitter-related therapies in development or currently being researched. We also review putative therapies that aim to slow disease progression by mechanisms not directly related to amyloid or tau.

引用

页数：21

共 94 条

[1] A Phase II study targeting amyloid-β with 3APS in mild-to-moderate Alzheimer disease [J].

Aisen, P. S. ;

Saumier, D. ;

Briand, R. ;

Laurin, J. ;

Gervais, F. ;

Tremblay, P. ;

Garceau, D. .

NEUROLOGY, 2006, 67 (10) :1757-1763

[2] High-dose B vitamin supplementation and cognitive decline in Alzheimer disease - A randomized controlled trial [J].

Aisen, Paul S. ;

Schneider, Lon S. ;

Sano, Mary ;

Diaz-Arrastia, Ramon ;

van Dyck, Christopher H. ;

Weiner, Myron F. ;

Bottiglieri, Teodoro ;

Jin, Shelia ;

Stokes, Karen T. ;

Thomas, Ronald G. ;

Thal, Leon J. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 300 (15) :1774-1783

[3] Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression - A randomized controlled trial [J].

Aisen, PS ;

Schafer, KA ;

Grundman, M ;

Pfeiffer, E ;

Sano, M ;

Davis, KL ;

Farlow, MR ;

Jin, S ;

Thomas, RG ;

Thal, LJ .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (21) :2819-2826

[4] A randomized controlled trial of prednisone in Alzheimer's disease [J].

Aisen, PS ;

Davis, KL ;

Berg, JD ;

Schafer, K ;

Campbell, K ;

Thomas, RG ;

Weiner, MF ;

Farlow, MR ;

Sano, M ;

Grundman, M ;

Thal, LJ .

NEUROLOGY, 2000, 54 (03) :588-593

[5] The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease [J].

Albert, Marilyn S. ;

DeKosky, Steven T. ;

Dickson, Dennis ;

Dubois, Bruno ;

Feldman, Howard H. ;

Fox, Nick C. ;

Gamst, Anthony ;

Holtzman, David M. ;

Jagust, William J. ;

Petersen, Ronald C. ;

Snyder, Peter J. ;

Carrillo, Maria C. ;

Thies, Bill ;

Phelps, Creighton H. .

ALZHEIMERS & DEMENTIA, 2011, 7 (03) :270-279

[6]

Bachurin S, 2001, ANN NY ACAD SCI, V939, P425

[7]

Bakchine S, 2008, J ALZHEIMERS DIS, V13, P97

[8] The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease [J].

Ballard, C ;

Waite, J .

COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2006, (01)

[9] The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial [J].

Ballard, Clive ;

Hanney, Maria Luisa ;

Theodoulou, Megan ;

Douglas, Simon ;

McShane, Rupert ;

Kossakowski, Katja ;

Gill, Randeep ;

Juszczak, Edmund ;

Yu, Ly-Mee ;

Jacoby, Robin .

LANCET NEUROLOGY, 2009, 8 (02) :151-157

[10]

Bentham P, 2004, LANCET, V363, P2105

← 1 2 3 4 5 6 7 8 9 10 →